All In Biotech

Drug Trial Radar · NCT03568422

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination With Weekly Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

37

Actual

Start

Feb 5, 2019

Primary completion

Nov 21, 2022

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Canadian Cancer Trials GroupResearch network
Sponsor type
Research network
Collaborators
Stand Up To Cancer; Canadian Breast Cancer Foundation; Ontario Institute for Cancer Research
First posted
Jun 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of disease and relieve some symptoms of cancer. One of the standard types of chemotherapy is a drug called paclitaxel (Taxol) given in a low dose every week for three out of four weeks. CFI-402257 is a new type of drug for breast cancer. Laboratory tests show that it may help slow the growth of breast cancer. This drug has been shown to shrink tumours in animals. CFI-402257 has been studied in a few people and appears well tolerated with little side effects. CFI-402257 seems promising but it is not clear if it can offer better results when given with paclitaxel compared to paclitaxel alone.

Conditions

  • Breast Cancer

Interventions

  • CFI-402257Drug

    Orally taken on intermittent schedule (days 1, 2, 8, 9, 15 \& 16

  • PaclitaxelDrug

    80 mg/m2 IV days 1, 8 \& 15 every 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Recommended Phase II Dose for CFI-402257Time frame: During cycle 1 (28 days)
  2. Phase II: Overall Response Rate Using RECIST 1.1Time frame: 2 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • Kingston Health Sciences Centre

    Kingston, Ontario, Canada

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • University Health Network

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.